Therapies for Chronic Spontaneous Urticaria: Present and Future Developments
Pharmaceuticals · 07.11.2024 · 17 (11) · 1499
DOI: 10.3390/ph17111499 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 07.11.2024. Verfasst von Riccardo Asero und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinica San Carlo, Ambulatorio di Allergologia, 20037 Paderno Dugnano, Italy. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 248 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Milan, Italian Ministry of Health.
Abstract (Originalsprache)
Chronic spontaneous urticaria (CSU) is a complex dermatological condition characterized by recurrent wheals and/or angioedema lasting for more than six weeks, significantly impairing patients’ quality of life. According to European guidelines, the first step in treatment involves second-generation H1-antihistamines (sgAHs), which block peripheral H1 receptors to alleviate symptoms. In cases with inadequate responses, the dose of antihistamines can be increased by up to fourfold. If symptoms persist despite this adjustment, the next step involves the use of omalizumab, a monoclonal anti-IgE antibody, which has shown efficacy in the majority of cases. However, a subset of patients remains refractory, necessitating alternative treatments such as immunosuppressive agents like cyclosporine or azathioprine. To address these unmet needs, several new therapeutic targets are being explored. Among them, significant attention is being given to drugs that block Bruton’s tyrosine kinase (BTK), such as remibrutinib, which reduces mast cell activation. Therapies like dupilumab, which target the interleukin-4 (IL-4) and IL-13 pathways, are also under investigation. Additionally, molecules targeting the Mas-related G protein-coupled receptor X2 (MRGPRX2), and those inhibiting the tyrosine kinase receptor Kit, such as barzolvolimab, show promise in clinical studies. These emerging treatments offer new options for patients with difficult-to-treat CSU and have the potential to modify the natural course of the disease by targeting key immune pathways, helping to achieve longer-term remission. Further research is essential to better elucidate the pathophysiology of CSU and optimize treatment protocols to achieve long-term benefits in managing this condition. Altogether, the future of CSU treatments that target pathogenetic mechanisms seems promising.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinica San Carlo, Ambulatorio di Allergologia, 20037 Paderno Dugnano, Italy.
- Department of Pathophysiology and Transplantation, Scuola di Specializzazione, Allergologia e Immunologia Clinica, Università degli Studi di Milano, 20122 Milan, Italy.
- Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, Italy.
- Department of Pathophysiology and Transplantation, Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, 20122 Milan, Italy.
ORCID-Profile: Riccardo Asero, Silvia Vaienti, Massimo Cugno
Förderung
- University of Milan
- Italian Ministry of Health
Zitieren
APA
Asero, R., Calzari, P., Vaienti, S., & Cugno, M. (2024). Therapies for Chronic Spontaneous Urticaria: Present and Future Developments. Pharmaceuticals, 17(11), 1499. https://doi.org/10.3390/ph17111499
Vancouver
Asero R, Calzari P, Vaienti S, Cugno M. Therapies for Chronic Spontaneous Urticaria: Present and Future Developments. Pharmaceuticals. 2024;17(11):1499. doi:10.3390/ph17111499
BibTeX
@article{Asero2024,
author = {Asero, Riccardo and Calzari, Paolo and Vaienti, Silvia and Cugno, Massimo},
title = {Therapies for Chronic Spontaneous Urticaria: Present and Future Developments},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {11},
pages = {1499},
doi = {10.3390/ph17111499}
}
EUVIMED